Targeting EGFR in bilio-pancreatic and liver carcinoma

Maria Elisabetta Fratto, Daniele Santini, Bruno Vincenzi, Nicola Silvestris, Amalia Azzariti, Stefania Tommasi, Alice Zoccoli, Sara Galluzzo, Evaristo Maiello, Giuseppe Colucci, Giuseppe Tonini

Research output: Contribution to journalArticle

Abstract

The key role of epidermal growth factor receptor (EGFR) in tumorigenesis has been demonstrated in several cancer types, so recent clinical trials have investigated their activity/efficacy in different settings. Two different types of EGFR-targeted agents were developed: monoclonal antibodies such as cetuximab and panitumumab, and tyrosine kinase inhibitors, such as gefitinib and erlotinib. In this review, we summarize the preclinical rational of potential activity and the most important clinical trials evaluated anti-EGFR targeted agents in non-colorectal digestive cancer, both in monotherapy and in combination with other chemotherapeutic or targeted agents. Patient selection by use of biologic markers will identify which patients are more likely to respond, contributing to the successful use of these agents.

Original languageEnglish
Pages (from-to)16-22
Number of pages7
JournalFrontiers in Bioscience - Scholar
Volume3 S
Issue number1
Publication statusPublished - Jan 1 2011

Fingerprint

Epidermal Growth Factor Receptor
Liver
Clinical Trials
Protein-Tyrosine Kinases
Patient Selection
Neoplasms
Carcinogenesis
Biomarkers
Monoclonal Antibodies
Pancreatic Carcinoma

Keywords

  • Anti-EGFR therapy
  • Biliary Tract Cancer
  • Gastric Cancer
  • Hepatocellular Cancer
  • Pancreatic Cancer
  • Review

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Immunology and Microbiology(all)
  • Medicine(all)

Cite this

Fratto, M. E., Santini, D., Vincenzi, B., Silvestris, N., Azzariti, A., Tommasi, S., ... Tonini, G. (2011). Targeting EGFR in bilio-pancreatic and liver carcinoma. Frontiers in Bioscience - Scholar, 3 S(1), 16-22.

Targeting EGFR in bilio-pancreatic and liver carcinoma. / Fratto, Maria Elisabetta; Santini, Daniele; Vincenzi, Bruno; Silvestris, Nicola; Azzariti, Amalia; Tommasi, Stefania; Zoccoli, Alice; Galluzzo, Sara; Maiello, Evaristo; Colucci, Giuseppe; Tonini, Giuseppe.

In: Frontiers in Bioscience - Scholar, Vol. 3 S, No. 1, 01.01.2011, p. 16-22.

Research output: Contribution to journalArticle

Fratto, ME, Santini, D, Vincenzi, B, Silvestris, N, Azzariti, A, Tommasi, S, Zoccoli, A, Galluzzo, S, Maiello, E, Colucci, G & Tonini, G 2011, 'Targeting EGFR in bilio-pancreatic and liver carcinoma', Frontiers in Bioscience - Scholar, vol. 3 S, no. 1, pp. 16-22.
Fratto ME, Santini D, Vincenzi B, Silvestris N, Azzariti A, Tommasi S et al. Targeting EGFR in bilio-pancreatic and liver carcinoma. Frontiers in Bioscience - Scholar. 2011 Jan 1;3 S(1):16-22.
Fratto, Maria Elisabetta ; Santini, Daniele ; Vincenzi, Bruno ; Silvestris, Nicola ; Azzariti, Amalia ; Tommasi, Stefania ; Zoccoli, Alice ; Galluzzo, Sara ; Maiello, Evaristo ; Colucci, Giuseppe ; Tonini, Giuseppe. / Targeting EGFR in bilio-pancreatic and liver carcinoma. In: Frontiers in Bioscience - Scholar. 2011 ; Vol. 3 S, No. 1. pp. 16-22.
@article{505692c95d7f460db10e4cdb93362e21,
title = "Targeting EGFR in bilio-pancreatic and liver carcinoma",
abstract = "The key role of epidermal growth factor receptor (EGFR) in tumorigenesis has been demonstrated in several cancer types, so recent clinical trials have investigated their activity/efficacy in different settings. Two different types of EGFR-targeted agents were developed: monoclonal antibodies such as cetuximab and panitumumab, and tyrosine kinase inhibitors, such as gefitinib and erlotinib. In this review, we summarize the preclinical rational of potential activity and the most important clinical trials evaluated anti-EGFR targeted agents in non-colorectal digestive cancer, both in monotherapy and in combination with other chemotherapeutic or targeted agents. Patient selection by use of biologic markers will identify which patients are more likely to respond, contributing to the successful use of these agents.",
keywords = "Anti-EGFR therapy, Biliary Tract Cancer, Gastric Cancer, Hepatocellular Cancer, Pancreatic Cancer, Review",
author = "Fratto, {Maria Elisabetta} and Daniele Santini and Bruno Vincenzi and Nicola Silvestris and Amalia Azzariti and Stefania Tommasi and Alice Zoccoli and Sara Galluzzo and Evaristo Maiello and Giuseppe Colucci and Giuseppe Tonini",
year = "2011",
month = "1",
day = "1",
language = "English",
volume = "3 S",
pages = "16--22",
journal = "Frontiers in Bioscience - Scholar",
issn = "1945-0516",
publisher = "Frontiers in Bioscience",
number = "1",

}

TY - JOUR

T1 - Targeting EGFR in bilio-pancreatic and liver carcinoma

AU - Fratto, Maria Elisabetta

AU - Santini, Daniele

AU - Vincenzi, Bruno

AU - Silvestris, Nicola

AU - Azzariti, Amalia

AU - Tommasi, Stefania

AU - Zoccoli, Alice

AU - Galluzzo, Sara

AU - Maiello, Evaristo

AU - Colucci, Giuseppe

AU - Tonini, Giuseppe

PY - 2011/1/1

Y1 - 2011/1/1

N2 - The key role of epidermal growth factor receptor (EGFR) in tumorigenesis has been demonstrated in several cancer types, so recent clinical trials have investigated their activity/efficacy in different settings. Two different types of EGFR-targeted agents were developed: monoclonal antibodies such as cetuximab and panitumumab, and tyrosine kinase inhibitors, such as gefitinib and erlotinib. In this review, we summarize the preclinical rational of potential activity and the most important clinical trials evaluated anti-EGFR targeted agents in non-colorectal digestive cancer, both in monotherapy and in combination with other chemotherapeutic or targeted agents. Patient selection by use of biologic markers will identify which patients are more likely to respond, contributing to the successful use of these agents.

AB - The key role of epidermal growth factor receptor (EGFR) in tumorigenesis has been demonstrated in several cancer types, so recent clinical trials have investigated their activity/efficacy in different settings. Two different types of EGFR-targeted agents were developed: monoclonal antibodies such as cetuximab and panitumumab, and tyrosine kinase inhibitors, such as gefitinib and erlotinib. In this review, we summarize the preclinical rational of potential activity and the most important clinical trials evaluated anti-EGFR targeted agents in non-colorectal digestive cancer, both in monotherapy and in combination with other chemotherapeutic or targeted agents. Patient selection by use of biologic markers will identify which patients are more likely to respond, contributing to the successful use of these agents.

KW - Anti-EGFR therapy

KW - Biliary Tract Cancer

KW - Gastric Cancer

KW - Hepatocellular Cancer

KW - Pancreatic Cancer

KW - Review

UR - http://www.scopus.com/inward/record.url?scp=79955946001&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79955946001&partnerID=8YFLogxK

M3 - Article

C2 - 21196353

AN - SCOPUS:79955946001

VL - 3 S

SP - 16

EP - 22

JO - Frontiers in Bioscience - Scholar

JF - Frontiers in Bioscience - Scholar

SN - 1945-0516

IS - 1

ER -